Iris H C Miedema

8PUBLICATIONS
38CO-AUTHORS
Molecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 10, 2024
A minimal physiologically-based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti-LAG-3 monoclonal antibody.

Robin Michelet, Klas Petersson, Marc C Huisman

|Sep 09, 2024
Secretome and immune cell attraction analysis of head and neck cancers.

Tara Muijlwijk, Niels E Wondergem, Fatima Ekhlas

|Jul 22, 2024
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.

Niels E Wondergem, Iris H C Miedema, Rieneke van de Ven

|Jun 17, 2024
Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by 18F-BMS986-192 PET: pooled analysis of data from four solid tumor types.

Iris H C Miedema, Johanna E E Pouw, Anne Kwakman

|Dec 09, 2023
89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs.

Iris H C Miedema, Jessica E Wijngaarden, Johanna E E Pouw

|Mar 01, 2023
89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.

Iris H C Miedema, Marc C Huisman, Gerben J C Zwezerijnen

Pageof 2

Frequent Collaborators

4 joint publications

C Willemien Menke-van der Houven van Oordt

3 joint publications

Rieneke van de Ven

3 joint publications

Gerben J C Zwezerijnen

2 joint publications

Ruud H Brakenhoff